These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 30788048)

  • 1. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review.
    Raj H; Durgia H; Palui R; Kamalanathan S; Selvarajan S; Kar SS; Sahoo J
    World J Diabetes; 2019 Feb; 10(2):114-132. PubMed ID: 30788048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials.
    Alfayez AI; Alfallaj JM; Mobark MA; Alalwan AA; Alfayez OM
    Curr Diabetes Rev; 2024; 20(2):e250523217349. PubMed ID: 37231725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
    Yabiku K
    Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials.
    Gu Y; Sun L; Zhang W; Kong T; Zhou R; He Y; Deng C; Yang L; Kong J; Chen Y; Shi J; Hu Y
    Front Pharmacol; 2023; 14():1102792. PubMed ID: 36992825
    [No Abstract]   [Full Text] [Related]  

  • 6. Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes.
    Sinha B; Datta D; Ghosal S
    JGH Open; 2021 Feb; 5(2):219-227. PubMed ID: 33553659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hameed I; Hayat J; Marsia S; Samad SA; Khan R; Siddiqui OM; Khan MO; Malik S; Fatima K; Fudim M; Krasuski RA
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102111. PubMed ID: 36931466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review.
    Kaur S; Sojitra V; Zahra A; Hutchinson J; Folawemi O; Bittla P; Ramphall S
    Cureus; 2023 Sep; 15(9):e45789. PubMed ID: 37745748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials.
    Lee KW; Devaraj NK; Ching SM; Veettil SK; Hoo FK; Deuraseh I; Soo MJ
    Oman Med J; 2021 May; 36(3):e273. PubMed ID: 34239714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mendelian randomisation reveals Sodium-glucose Cotransporter-1 inhibition's potential in reducing Non-Alcoholic Fatty Liver Disease risk.
    Dobbie LJ; Cuthbertson DJ; Hydes TJ; Alam U; Zhao SS
    Eur J Endocrinol; 2023 Jun; 188(6):K33-K37. PubMed ID: 37343141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
    Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
    Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis.
    Yan H; Huang C; Shen X; Li J; Zhou S; Li W
    Front Endocrinol (Lausanne); 2022; 13():923606. PubMed ID: 35909522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Luo Q; Wei R; Cai Y; Zhao Q; Liu Y; Liu WJ
    Front Med (Lausanne); 2022; 9():793203. PubMed ID: 35280867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews.
    Shao SC; Kuo LT; Chien RN; Hung MJ; Lai EC
    BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33268450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
    Shinozaki S; Tahara T; Lefor AK; Ogura M
    J Med Invest; 2020; 67(3.4):280-284. PubMed ID: 33148902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Xing B; Zhao Y; Dong B; Zhou Y; Lv W; Zhao W
    J Diabetes Investig; 2020 Sep; 11(5):1238-1247. PubMed ID: 32083798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review.
    Xu R; Lian D; Xie Y; Chen Z; Wang Y; Mu L; Wang Y; Zhang B
    Front Biosci (Landmark Ed); 2023 Jul; 28(7):134. PubMed ID: 37525911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Amjad W; Malik A; Qureshi W; Dennis B; Mumtaz M; Haider R; Jamal S; Jaura F; Ahmed A
    Prz Gastroenterol; 2022; 17(4):288-300. PubMed ID: 36514450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease.
    Yamashima M; Miyaaki H; Miuma S; Shibata H; Sasaki R; Haraguchi M; Fukushima M; Nakao K
    Intern Med; 2019; 58(14):1987-1992. PubMed ID: 31308341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.